Personalis (PSNL) – Analysts’ Recent Ratings Updates

Personalis (NASDAQ: PSNL) has recently received a number of price target changes and ratings updates:

• 7/21/2026 – Personalis was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/20/2026 – Personalis was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $16.25 price target on the stock.
• 7/20/2026 – Personalis had its price target raised by BTIG Research from $11.00 to $16.25. They now have a “buy” rating on the stock.
• 7/20/2026 – Personalis was downgraded by Needham & Company LLC from “buy” to “hold”.
• 7/17/2026 – Personalis had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/17/2026 – Personalis had its price target raised by Needham & Company LLC from $12.00 to $17.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Personalis had its “buy” rating reaffirmed by TD Cowen.
• 7/9/2026 – Personalis had its price target raised by Morgan Stanley from $9.00 to $13.00. They now have an “equal weight” rating on the stock.
• 6/13/2026 – Personalis was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 4,982 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. The trade was a 29.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 435,032 shares of company stock valued at $5,599,929. Insiders own 4.20% of the company’s stock.

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.